Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular di...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Guntram Schernthaner, Avraham Karasik, Agn ė Abraitienė, Alexander S. Ametov, Zsolt Gaàl, Janusz Gumprecht, Andrej Janež, Susanne Kaser, Katarina Lalić, Boris N. Mankovsky, Evgeny Moshkovich, Marju Past, Martin Prázný, Gabriela Radulian, Lea Smirč Tags: Commentary Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance | Study